BACKGROUND
Ruzaltatug rezetecan is a novel HER3-directed antibody-drug conjugate that has shown promising antitumour activity and manageable safety in pretreated EGFR-.mutated non-small-cell lung cancer (NSCLC) in a phase 1 trial. We aimed to compare the efficacy and safety of ruzaltatug rezetecan with chemotherapy in...
Chong-Rui Xu, Yan Zhang, G. Lin et al.· The Lancet· 1 citation
SUNRAY-02 is a 2-part global, placebo-controlled phase III study recruiting patients with stage II-III KRAS G12C-mutant NSCLC following definitive therapy, addressing a critical treatment gap in KRAS G12C-mutant early-stage NSCLC.
J. Chaft, J. Lee, Suresh Senan et al.· Future Oncology· 0 citations
Improvements in physical and mental HRQoL were maintained over 2 years of active treatment and a clinically meaningful difference in improvement from baseline was seen at week 12 for bodily pain, role physical, mental health, social functioning, and vitality SF-36v2 domains with alectinib.
R. Dziadziuszko, J. S. Ahn, F. Barlesi et al.· The Lancet Oncology· 0 citations
INTRODUCTION
In ADAURA, adjuvant osimertinib improved DFS and OS versus placebo in resected EGFR-mutated stage IB-IIIA NSCLC. We report a post hoc exploratory analysis of long-term OS post-adjuvant treatment completion.
METHODS
Patients (N = 682) were randomized to osimertinib or placebo until recurrence, treatment c...
Yi-Long Wu, M. Majem, T. John et al.· Journal of Thoracic Oncology· 1 citation
In patients with NSCLC, in patients with NSCLC, down-regulation of FUS or up-regulation of CD36 or SYP was associated with progression to LM, highlighting CD36 as a promising therapeutic target to limit the progression of LM.
Shou-Heng Lin, Kai Yin, M. Zheng et al.· Science Translational Medici...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.